Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 5/17/13  and contains information from public web pages and contributions from the ZoomInfo community.

Mark A. Ashwell

Wrong Mark A. Ashwell?

Vice President, Medicinal Chemist...

Phone: (781) ***-****  HQ Phone
Email: m***@***.com
Local Address:  Cambridge , Massachusetts , United States
ArQule , Inc.
19 Presidential Way
Woburn , Massachusetts 01801
United States

Company Description: ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company’s product is ARQ 197, an orally...   more

Employment History

Board Memberships and Affiliations


  • Ph.D.
17 Total References
Web References
CHI's Molecular Medicine Tri-Conference 2006 | Track 3 Mastering Medicinal Chemistry, 21 Feb 2006 [cached]
Dr. Mark Ashwell, Vice President, Medicinal Chemistry, ArQules Drug Discovery Chemistry
Dr. Mark Ashwell is Vice President of Medicinal Chemistry and Head of ArQule's Drug Discovery Chemistry.
Dr. Mark Ashwell, Vice President, Medicinal Chemistry, ArQule
CHI's Molecular Medicine Tri-Conference, 13 Oct 2004 [cached]
Dr. Mark Ashwell, Director of Chemistry, Arqule Inc.
Dr. Mark Ashwell, Director of Medicinal Chemistry, Arqule, Inc.
Mastering Medicinal Chemistry - Day 1 - Molecular Med Tri-Con 2012, 8 Mar 2011 [cached]
Mark Ashwell, Ph.D., Vice President, Medicinal Chemistry, ArQule, Inc.
"Since 2007, we have focused ..., 25 July 2012 [cached]
"Since 2007, we have focused ArQule's efforts in drug discovery to leverage our learnings in the parallel chemistry business together with our structural analysis of inactive kinases," ArQule's vp of chemistry Mark Ashwell, Ph.D., explained to GEN.
ArQule's lead drug candidate is tivantinib, a c-MET kinase inhibitor currently in clinical trials for non-small-cell lung cancer (NSCLC). The company expects that it will enter Phase III trials to test its efficacy in liver cancer in late 2012/early 2013.
"The story of tivantinib's discovery is unusual," Dr. Ashwell said. "We found it while screening a small molecule kinase library in a cellular assay, looking for a cell signature that we felt would lead to an anticancer agent.
"We found the profile we were looking for, and discovered that the activity came from only one of a pair of enantiomers, leading us to conclude that the active small molecule had a highly specific target with a strict molecular recognition requirement."
Dr. Ashwell noted that he and his colleagues screened the compound against a group of kinases and found it was a c-MET inhibitor.
Since then, he said, "We have been able to look at the activation states of kinases in very specific ways, and we found tivantinib prevents cMET from assuming an activated form.
Next-Gen Kinase Inhibitors, 8 Feb 2012 [cached]
Mark Ashwell, ArQule Inc
Other People with the name "Ashwell":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.